ScoreWhy is Fredun Pharmaceuticals Ltd ?
1
Healthy long term growth as Net Sales has grown by an annual rate of 34.99% and Operating profit at 62.66%
2
With a growth in Net Profit of 94.53%, the company declared Outstanding results in Jun 26
- The company has declared positive results for the last 9 consecutive quarters
- OPERATING CF(Y) Highest at Rs 16.44 Cr
- NET SALES(Q) Highest at Rs 228.25 cr
- OPERATING PROFIT TO INTEREST(Q) Highest at 3.80 times
3
With ROCE of 19.9, it has a Fair valuation with a 5 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 244.93%, its profits have risen by 89.6% ; the PEG ratio of the company is 0.7
4
Market Beating performance in long term as well as near term
- Along with generating 244.93% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Fredun Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Fredun Pharma for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Fredun Pharma
244.93%
4.60
53.19%
Sensex
-1.65%
-0.12
13.58%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
34.99%
EBIT Growth (5y)
62.66%
EBIT to Interest (avg)
2.59
Debt to EBITDA (avg)
2.93
Net Debt to Equity (avg)
0.56
Sales to Capital Employed (avg)
1.62
Tax Ratio
24.83%
Dividend Payout Ratio
1.15%
Pledged Shares
0
Institutional Holding
4.00%
ROCE (avg)
15.49%
ROE (avg)
12.48%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
46
Industry P/E
37
Price to Book Value
7.26
EV to EBIT
21.69
EV to EBITDA
19.72
EV to Capital Employed
5.00
EV to Sales
2.92
PEG Ratio
0.73
Dividend Yield
0.04%
ROCE (Latest)
19.94%
ROE (Latest)
15.95%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend38What is working for the Company
OPERATING CF(Y)
Highest at Rs 16.44 Cr
NET SALES(Q)
Highest at Rs 228.25 cr
OPERATING PROFIT TO INTEREST(Q)
Highest at 3.80 times
PBDIT(Q)
Highest at Rs 32.74 cr.
PAT(Q)
Highest at Rs 13.13 cr.
DEBT-EQUITY RATIO(HY)
Lowest at 0.80 times
PBT LESS OI(Q)
Highest at Rs 20.55 cr.
-7What is not working for the Company
INTEREST(Latest six months)
At Rs 23.11 cr has Grown at 26.42%
Loading Valuation Snapshot...
Here's what is working for Fredun Pharma
Net Sales - Quarterly
At Rs 228.25 cr has Grown at 90.45%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 20.55 cr has Grown at 127.32%
Year on Year (YoY)MOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 13.13 cr has Grown at 93.9%
Year on Year (YoY)MOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Quarterly
Highest at Rs 228.25 cr and Grown
each quarter in the last five quartersMOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Operating Profit to Interest - Quarterly
Highest at 3.80 times
in the last five quartersMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Operating Profit (PBDIT) - Quarterly
Highest at Rs 32.74 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 13.13 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Operating Cash Flow - Annually
Highest at Rs 16.44 Cr
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 20.55 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Debt-Equity Ratio - Half Yearly
Lowest at 0.80 times
in the last five half yearly periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Here's what is not working for Fredun Pharma
Interest - Latest six months
At Rs 23.11 cr has Grown at 26.42%
over previous Half yearly periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (Rs cr)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
